A Serevent lawsuit is an option for COPD patients who suffered a serious cardiovascular event within the first 30 days of initiating treatment with the Serevent long-acting inhaler.
The nationwide law firm of Bernstein Liebhard LLP is evaluating potential Serevent lawsuits on behalf of COPD patients who experienced serious heart problems in the first 30 days of new treatment with this inhaled medication, including:
To contact an experienced Serevent lawyer today, please call (888) 994-5118.
Serevent is an inhaled long-acting β2-agonists (LABAs) used to treat people with asthma, chronic obstructive pulmonary disease (COPD) or other chronic airway problems. Unlike fast-acting rescue inhalers, Serevent and other LABAs are designed for daily use to control bronchospasms associated with these conditions.
The labels for Serevent and other single-ingredient LABAs include a Black Box Warning – the strongest possible safety alert – regarding an association with asthma-related death.
In January 2018, a study published in JAMA Internal Medicine suggested that COPD patients who were new users of certain inhaled asthma drugs – including Serevent and other LABAs – faced a significantly increased risk for heart problems during the first 30 days of treatment.
The study drew data from medical records involving more than 280,000 COPD patients in Taiwan, all of whom had been prescribed inhaled LABAs or antimuscarinic antagonists (LAMAs) from 2007 to 2011,
The average age of the study subjects was 71.4 and 68.9 percent were men.
The average follow-up was 2 years, with the research team comparing hospital visits for coronary artery disease, heart failure, ischemic stroke or arrhythmia to duration since initiation of long-acting inhaler therapy.
The analysis suggested that patients faced a 50% increased risk for heart problems during the first 30 days of treatment with Serevent or another long-acting inhaler is initiated. However, those who previously used an LABA or LAMA saw their risk drop when they went back on their inhaler more than 30 days later, leading the study authors to concluded that the cardiovascular risk associated with the medications peaked at roughly 30 days after treatment initiation, fell from 31 to 60 days on, and reduced below baseline from 71 to 240 days.
“We have provided the first evidence to indicate that new use and duration since initiation of inhaled long-acting bronchodilators are associated with the therapy-related risk of CVD in patients with COPD,” the study authors wrote.
They suggested that COPD patients be assessed for cardiovascular risk prior to initiating new treatment with a long-acting inhaler.
“Health care professionals should be vigilant for any cardiovascular symptoms during the first 30 days of inhalation therapy. Given that CVD is highly prevalent among patients with COPD, clinicians should also pay attention to the management of CVD risk factors throughout the duration of LABA or LAMA therapy,” they continued.
COPD patients who develop heart problems after initiating new treatment with Serevent, or their surviving loved ones, may be entitled to compensation for:
For a free, no-obligation review of you potential Serevent lawsuit, please contact our office today by completing our online form or call (888) 994-5118.
Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.